In this work we reveal that the expression of CD80 and/or CD86 is upregulated in most DLBCL patients receiving CAR T cell therapy and that a co-targeting CAR/CCR (chimeric checkpoint receptor) design increases both efficacy and safety of the CD19-specific CAR T cells compared with T cells expressing a 2nd Gen CAR T construct. The gene discussed is CD86; the disease is diffuse large B-cell lymphoma.